CN1237052C - 用作钾通道抑制剂的邻位取代的含氮双芳基化合物 - Google Patents

用作钾通道抑制剂的邻位取代的含氮双芳基化合物 Download PDF

Info

Publication number
CN1237052C
CN1237052C CNB018201814A CN01820181A CN1237052C CN 1237052 C CN1237052 C CN 1237052C CN B018201814 A CNB018201814 A CN B018201814A CN 01820181 A CN01820181 A CN 01820181A CN 1237052 C CN1237052 C CN 1237052C
Authority
CN
China
Prior art keywords
phenyl
alkyl
hydrogen
carbon atom
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018201814A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537102A (zh
Inventor
S·波伊克特
J·布兰德尔
H·赫梅勒
H-W·克里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1537102A publication Critical patent/CN1537102A/zh
Application granted granted Critical
Publication of CN1237052C publication Critical patent/CN1237052C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CNB018201814A 2000-12-07 2001-11-24 用作钾通道抑制剂的邻位取代的含氮双芳基化合物 Expired - Fee Related CN1237052C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10060807.8 2000-12-07
DE10060807A DE10060807A1 (de) 2000-12-07 2000-12-07 Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Publications (2)

Publication Number Publication Date
CN1537102A CN1537102A (zh) 2004-10-13
CN1237052C true CN1237052C (zh) 2006-01-18

Family

ID=7666129

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018201814A Expired - Fee Related CN1237052C (zh) 2000-12-07 2001-11-24 用作钾通道抑制剂的邻位取代的含氮双芳基化合物

Country Status (30)

Country Link
US (1) US6794377B2 (enExample)
EP (1) EP1341764B1 (enExample)
JP (1) JP4445198B2 (enExample)
KR (1) KR100815070B1 (enExample)
CN (1) CN1237052C (enExample)
AR (1) AR033408A1 (enExample)
AT (1) ATE297897T1 (enExample)
AU (2) AU2002221892B2 (enExample)
BR (1) BR0116005A (enExample)
CA (1) CA2436891C (enExample)
CZ (1) CZ301923B6 (enExample)
DE (2) DE10060807A1 (enExample)
DK (1) DK1341764T3 (enExample)
EE (1) EE05220B1 (enExample)
ES (1) ES2242792T3 (enExample)
HR (1) HRP20030448B1 (enExample)
HU (1) HUP0302762A3 (enExample)
IL (2) IL156312A0 (enExample)
MX (1) MXPA03004966A (enExample)
NO (1) NO325297B1 (enExample)
NZ (1) NZ526294A (enExample)
PL (1) PL207057B1 (enExample)
PT (1) PT1341764E (enExample)
RU (1) RU2275360C2 (enExample)
SI (1) SI1341764T1 (enExample)
SK (1) SK286056B6 (enExample)
TW (1) TWI242005B (enExample)
WO (1) WO2002046162A1 (enExample)
YU (1) YU40203A (enExample)
ZA (1) ZA200303931B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA2474192C (en) 2002-02-12 2011-06-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US20050054673A1 (en) * 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US7419962B2 (en) * 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
CA2615440A1 (en) * 2005-07-22 2007-02-08 Merck & Co., Inc. Potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
AU2007245891B2 (en) * 2006-04-27 2012-10-18 Sanofi-Aventis Deutschland Gmbh Inhibitors of the TASK-1 and TASK-3 ion channel
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CA2768396A1 (en) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Dihydropyrimidone amides as p2x7 modulators
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2948433B1 (en) * 2013-01-22 2017-04-26 Technische Universität Graz Atglistatin as lipase inhibitor
WO2014183221A1 (en) * 2013-05-17 2014-11-20 The Centre For Drug Research And Development Resveratrol analogs and therapeutic uses thereof
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616002A (en) * 1984-11-09 1986-10-07 Ciba-Geigy Corporation Dihydro pyridine compounds, compositions and use
US5196537A (en) * 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
DE4430638A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
EP1109544A4 (en) * 1998-09-01 2004-10-27 Bristol Myers Squibb Co POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
RU2275360C2 (ru) 2006-04-27
DE10060807A1 (de) 2002-06-20
JP2004515493A (ja) 2004-05-27
MXPA03004966A (es) 2003-09-25
NZ526294A (en) 2005-04-29
CA2436891C (en) 2011-01-11
US6794377B2 (en) 2004-09-21
CZ20031564A3 (cs) 2003-09-17
SI1341764T1 (en) 2005-10-31
PT1341764E (pt) 2005-09-30
AR033408A1 (es) 2003-12-17
ATE297897T1 (de) 2005-07-15
SK286056B6 (sk) 2008-02-05
BR0116005A (pt) 2004-01-06
ZA200303931B (en) 2004-03-24
DE50106549D1 (de) 2005-07-21
EE05220B1 (et) 2009-10-15
HUP0302762A3 (en) 2010-03-29
US20030060470A1 (en) 2003-03-27
AU2002221892B2 (en) 2006-07-13
EP1341764B1 (de) 2005-06-15
JP4445198B2 (ja) 2010-04-07
HK1066539A1 (en) 2005-03-24
SK6872003A3 (en) 2004-02-03
EE200300225A (et) 2003-08-15
WO2002046162A1 (de) 2002-06-13
IL156312A (en) 2009-05-04
EP1341764A1 (de) 2003-09-10
KR20030081344A (ko) 2003-10-17
YU40203A (sh) 2006-05-25
AU2189202A (en) 2002-06-18
NO325297B1 (no) 2008-03-17
CN1537102A (zh) 2004-10-13
HRP20030448A2 (en) 2005-04-30
HUP0302762A2 (hu) 2003-11-28
NO20032488D0 (no) 2003-06-02
PL207057B1 (pl) 2010-10-29
CA2436891A1 (en) 2002-06-13
ES2242792T3 (es) 2005-11-16
IL156312A0 (en) 2004-01-04
KR100815070B1 (ko) 2008-03-20
NO20032488L (no) 2003-08-04
CZ301923B6 (cs) 2010-07-28
PL365318A1 (en) 2004-12-27
TWI242005B (en) 2005-10-21
HRP20030448B1 (en) 2006-06-30
DK1341764T3 (da) 2005-10-17

Similar Documents

Publication Publication Date Title
CN1237052C (zh) 用作钾通道抑制剂的邻位取代的含氮双芳基化合物
CN1290825C (zh) 邻位、间位取代的双芳基化合物、它们的制备方法、它们作为药物的用途和含有它们的药物制剂
CN1225463C (zh) 具有钾通道阻断作用的芳基化呋喃和噻吩甲酰胺
CN1522244A (zh) 邻氨基苯甲酰胺类化合物、其制备方法、其作为抗心律不齐剂的应用及其药物制剂
CN1157372C (zh) 二氢茚基取代的苯甲酰胺、其制备方法、其作为药物的应用、和含有它们的药物制剂
CN1217918C (zh) 氨基环己基醚化合物和其用途
CN1195738C (zh) 2′－取代的1,1′－联苯－2－甲酰胺、它们的制备方法、作为药物的用途和含有它们的药物制剂
CN1143852C (zh) 茚并、萘并和苯并芳庚并二氢噻唑衍生物、它们的制备和它们作为减食欲药物的用途
CN1261877A (zh) 4－溴或4－碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
CN1688548A (zh) 喹啉抗生素中间体的制备方法
CN1254337A (zh) N－羟基4－磺酰基丁酰胺化合物
CN1705635A (zh) 组蛋白脱乙酰酶抑制剂
CN1151157A (zh) 金属蛋白酶抑制剂
CN1492852A (zh) 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物
CN1859904A (zh) 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
CN1165815A (zh) 酚化合物及其制备方法
CN1441783A (zh) 含二氰基吡啶衍生物的药物
CN1542001A (zh) 旋转异构酶活性的小分子抑制剂
CN1788002A (zh) 作为钠通道阻滞剂的联芳基取代的三唑化合物
CN1630517A (zh) 包含含氮化合物的具有cxcr4拮抗作用的药物
CN1295561A (zh) N－杂环羧酸或羧酸等排物的n－结合氨磺酰
CN1324008C (zh) 作为组织蛋白酶抑制剂的新化合物和组合物
CN1402710A (zh) 抗细小核糖核酸病毒化合物和组合物,其药用,和其合成原料
CN1976920A (zh) N－型钙通道阻断剂
CN1922138A (zh) 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1066539

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060118

Termination date: 20111124